Hereditary Angioedema Patients Report Breakthrough Attacks on Current Injectable/Infused Prophylaxis Medication
June 06 2020 - 3:01AM
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented
findings from two patient surveys conducted to gain insights into
patients’ current hereditary angioedema (HAE) treatment
expectations, experience and satisfaction. Patient-reported attack
history shows patients treated with current injectable or infused
prophylactic medications (Takhzyro®, Haegarda®, Cinryze®) continue
to experience breakthrough attacks with a mean ranging from 0.9 to
1.8 attacks over the three months prior to survey.
In addition, the majority of patients surveyed
did not expect to have zero attacks even when taking prophylaxis
therapy.
The data were presented at the European Academy
of Allergy and Clinical Immunology (EAACI) Digital Congress.
“While the injectable and infused medications
introduced over the past 12 years have provided added prophylactic
attack control for HAE patients, most patients in the study
continue to experience breakthrough attacks, and medication
adherence continues to be a challenge. HAE patients have indicated
an interest in new preventative treatment options, with the
majority agreeing that they would prefer an oral medication,
despite liking their current prophylactic medication,” said Jinky
Rosselli, vice president of global business analysis and operations
at BioCryst, who conducted the research.
Study Methods and ResultsStudy
participants were U.S. adult patients with a diagnosis of Type I or
Type II HAE. Patients participated in surveys in 2018 (n=75)
and 2019 (n=100). Two patients participated in both surveys. The
patient surveys were conducted anonymously in compliance with the
EphMRA code of conduct.
- In the 2019 survey, 85 percent of
patients reported taking at least one medicine to prevent HAE
attacks, compared to 64 percent in the 2018 survey.
- The majority (89 percent) of
patients using prophylaxis in the 2019 survey reported using at
least one of the three most commonly prescribed injectable or
infused prophylactic therapies.
- Over the three months prior to the
survey, these patients reported a mean of 0.9, 1.6 and 1.8 attacks
while taking Haegarda®, Cinryze® and Takhzyro®, respectively.
Patients taking these injectable or infused therapies reported
similar attack rates in the 2018 study.
- In the 2019 survey, 21 percent of
patients using prophylaxis reported the expectation to have zero
attacks over the next 12 months.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule
medicines that treat rare diseases in which significant unmet
medical needs exist and an enzyme plays a key role in the
biological pathway of the disease. BioCryst has several ongoing
development programs including berotralstat (BCX7353), an oral
treatment for hereditary angioedema, BCX9930, an oral Factor D
inhibitor for the treatment of complement-mediated diseases,
galidesivir, a potential treatment for COVID-19, Marburg virus
disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the
treatment of fibrodysplasia ossificans progressiva. RAPIVAB®
(peramivir injection), a viral neuraminidase inhibitor for the
treatment of influenza, is BioCryst's first approved product and
has received regulatory approval in the U.S., Canada, Australia,
Japan, Taiwan, Korea and the European Union. Post-marketing
commitments for RAPIVAB are ongoing. For more information, please
visit the Company's website at www.BioCryst.com.
Forward-Looking StatementsThis
press release contains forward-looking statements, including
statements regarding future results, performance or achievements.
These statements involve known and unknown risks, uncertainties and
other factors which may cause BioCryst’s actual results,
performance or achievements to be materially different from any
future results, performances or achievements expressed or implied
by the forward-looking statements. These statements reflect our
current views with respect to future events and are based on
assumptions and are subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements. Some of the factors that could affect
the forward-looking statements contained herein include: that the
ongoing COVID-19 pandemic could create challenges in all aspects of
our business, including without limitation delays, stoppages,
difficulties and increased expenses with respect to our and our
partners’ development, regulatory processes and supply chains,
could negatively impact our ability to access the capital or credit
markets to finance our operations, or could have the effect of
heightening many of the risks described below or in the documents
we file periodically with the Securities and Exchange Commission;
that developing any HAE product candidate may take longer or may be
more expensive than planned; that ongoing and future preclinical
and clinical development of BCX9930, BCX9250 and galidesivir may
not have positive results; that BioCryst may not be able to enroll
the required number of subjects in planned clinical trials of
product candidates; that BioCryst may not advance human clinical
trials with product candidates as expected; that the FDA, EMA, PMDA
or other applicable regulatory agency may require additional
studies beyond the studies planned for product candidates, or may
not provide regulatory clearances which may result in delay of
planned clinical trials, or may impose a clinical hold with respect
to such product candidates, or withhold market approval for product
candidates; that actual financial results may not be consistent
with expectations, including that 2020 operating expenses and cash
usage may not be within management's expected ranges. Please
refer to the documents BioCryst files periodically with the
Securities and Exchange Commission, specifically BioCryst’s most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q,
and Current Reports on Form 8-K, all of which identify important
factors that could cause the actual results to differ materially
from those contained in BioCryst’s projections and forward-looking
statements.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Sep 2023 to Sep 2024